Research & Development Solution Center

81. MedImmune's Blueprint For Building A Biologics R&D Engine 5/30/2013

    Bahija Jallal, VP of translational science for MedImmune, has some insights on how to successfully focus your biologics R&D operation to encourage, not kill the entrepreneurial spirit on which it was built.

82. The Shifting Geography Of Life Sciences Innovation 5/30/2013

    The life science industry is experiencing change at a pace that is forcing companies to examine how they should operate and innovate more effectively.

83. Why Is The President Attacking The Successful Medicare Part D Program? 4/1/2013

    Medicare Part D has done a good job of reducing prescription drug spending. But the current administration is attacking it in order to control pharmaceutical pricing.

84. Protecting U.S. Medical Innovation – A Call To Action From Celgene's CEO 4/1/2013

    The U.S. has a long history of innovation. Bob Hugin, chairman and CEO of Celgene, believes that to create a prosperous future in medical innovation, industry leaders need to stand up and advocate for laws and public policy that support positive solutions.

85. Strategic Outsourcing Often Means Combining CROs 3/4/2013

    Functional CROs have expertise in a specific area, but offer a limited range of products. Full-service CROs offer a complete range of services but may not be fully integrated. Strategic outsourcing may now require you to combine them.

86. ADC: The Next Big Opportunity For Oncology Drugs 2/27/2013

    The commercial success of mAb products such as Rituxan, Erbitux, and Herceptin has catapulted mAbs to the forefront of molecular medicine.

87. Pfizer's Approach To Developing A Sustainable Business In Rare Disease R&D 2/27/2013

    UCB’s CEO, Roch Doliveux’s experience will tell you that in order to be successful in the pharmaceutical industry, you need to be successful in the United States.

88. Successful Drug Device Development Begins At The Earliest Stage 2/1/2013

    Lessons from Janssen, Allergan, and Boehringer Ingelheim show how successful drug-device development begins at the earliest possible stage.

89. The Race In Diabetes R&D 1/31/2013

    GSK and other drug discovery and development companies are taking new aim on the global diabetes explosion – sometimes alone, sometimes in league together.

90. Making Precompetitive Partnerships Work In Clinical Trials 12/28/2012

    J&J executives realized that to design the clinical trial process in the future they would have to look outside their walls and collaborate.